B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H2 2016

Published: Aug, 2016 | Pages: 147 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H2 2016', provides an overview of the B-Cell Chronic Lymphocytic Leukemia pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for B-Cell Chronic Lymphocytic Leukemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for B-Cell Chronic Lymphocytic Leukemia and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of B-Cell Chronic Lymphocytic Leukemia
- The report reviews pipeline therapeutics for B-Cell Chronic Lymphocytic Leukemia by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved B-Cell Chronic Lymphocytic Leukemia therapeutics and enlists all their major and minor projects
- The report assesses B-Cell Chronic Lymphocytic Leukemia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for B-Cell Chronic Lymphocytic Leukemia

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for B-Cell Chronic Lymphocytic Leukemia
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding B-Cell Chronic Lymphocytic Leukemia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
B-Cell Chronic Lymphocytic Leukemia Overview 10
Therapeutics Development 11
Pipeline Products for B-Cell Chronic Lymphocytic Leukemia - Overview 11
Pipeline Products for B-Cell Chronic Lymphocytic Leukemia - Comparative Analysis 12
B-Cell Chronic Lymphocytic Leukemia - Therapeutics under Development by Companies 13
B-Cell Chronic Lymphocytic Leukemia - Therapeutics under Investigation by Universities/Institutes 15
B-Cell Chronic Lymphocytic Leukemia - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
B-Cell Chronic Lymphocytic Leukemia - Products under Development by Companies 19
B-Cell Chronic Lymphocytic Leukemia - Products under Investigation by Universities/Institutes 21
B-Cell Chronic Lymphocytic Leukemia - Companies Involved in Therapeutics Development 22
AB Science SA 22
Aduro BioTech, Inc. 23
Amgen Inc. 24
Celgene Corporation 25
Cell Source, Inc. 26
Dynavax Technologies Corporation 27
Eisai Co., Ltd. 28
Elsalys Biotech SAS 29
F. Hoffmann-La Roche Ltd. 30
iDD biotech SAS 31
Immunomedics, Inc. 32
Johnson & Johnson 33
Juno Therapeutics Inc. 34
Lymphocyte Activation Technologies, S.A. 35
MedImmune, LLC 36
MEI Pharma, Inc. 37
Millennium Pharmaceuticals Inc 38
Molecular Templates Inc. 39
Noxxon Pharma AG 40
Ono Pharmaceutical Co., Ltd. 41
Regeneron Pharmaceuticals Inc 42
Sunesis Pharmaceuticals, Inc. 43
TheraMAB LLC 44
Unum Therapeutics, Inc. 45
B-Cell Chronic Lymphocytic Leukemia - Therapeutics Assessment 46
Assessment by Monotherapy Products 46
Assessment by Combination Products 47
Assessment by Target 48
Assessment by Mechanism of Action 50
Assessment by Route of Administration 52
Assessment by Molecule Type 54
Drug Profiles 56
202-b - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
AB-8779 - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
alemtuzumab biosimilar - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
alisertib - Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
AMG-319 - Drug Profile 65
Product Description 65
Mechanism Of Action 65
R&D Progress 65
BB-001 - Drug Profile 67
Product Description 67
Mechanism Of Action 67
R&D Progress 67
BION-1301 - Drug Profile 68
Product Description 68
Mechanism Of Action 68
R&D Progress 68
Cellular Immunotherapy for Chronic Lymphocytic Leukaemia - Drug Profile 69
Product Description 69
Mechanism Of Action 69
R&D Progress 69
Cellular Immunotherapy for Hematological Malignancies - Drug Profile 70
Product Description 70
Mechanism Of Action 70
R&D Progress 70
Cellular Immunotherapy to Activate 4-1BBL and to Target CD19 for B-Cell Malignancies - Drug Profile 71
Product Description 71
Mechanism Of Action 71
R&D Progress 71
Cellular Immunotherapy to Activate CD40L and to Target CD19 for B-Cell Malignancies - Drug Profile 73
Product Description 73
Mechanism Of Action 73
R&D Progress 73
Cellular Immunotherapy to Activate IL-12 and to Target CD19 for B-Cell Malignancies - Drug Profile 75
Product Description 75
Mechanism Of Action 75
R&D Progress 75
Cellular Immunotherapy to Target CD16 for B-Cell Non-Hodgkin Lymphoma and B-Cell Chronic Lymphocytic Leukemia - Drug Profile 77
Product Description 77
Mechanism Of Action 77
R&D Progress 77
Cellular Immunotherapy to Target CD19 for B-Cell Chronic Lymphocytic Leukemia - Drug Profile 78
Product Description 78
Mechanism Of Action 78
R&D Progress 78
Cellular Immunotherapy to Target CD19 for B-Cell Malignancies - Drug Profile 79
Product Description 79
Mechanism Of Action 79
R&D Progress 79
Cellular Immunotherapy to Target CD19 for Oncology - Drug Profile 80
Product Description 80
Mechanism Of Action 80
R&D Progress 80
Cellular Immunotherapy to Target CD19 for Oncology - Drug Profile 81
Product Description 81
Mechanism Of Action 81
R&D Progress 81
Cellular Immunotherapy to Target CD19 for Oncology - Drug Profile 82
Product Description 82
Mechanism Of Action 82
R&D Progress 82
durvalumab - Drug Profile 83
Product Description 83
Mechanism Of Action 83
R&D Progress 83
E-7449 - Drug Profile 93
Product Description 93
Mechanism Of Action 93
R&D Progress 93
IDD-001 - Drug Profile 94
Product Description 94
Mechanism Of Action 94
R&D Progress 94
IDD-002 - Drug Profile 95
Product Description 95
Mechanism Of Action 95
R&D Progress 95
JNJ-64052781 - Drug Profile 96
Product Description 96
Mechanism Of Action 96
R&D Progress 96
lenalidomide - Drug Profile 98
Product Description 98
Mechanism Of Action 98
R&D Progress 98
MAT-303 - Drug Profile 112
Product Description 112
Mechanism Of Action 112
R&D Progress 112
ME-401 - Drug Profile 113
Product Description 113
Mechanism Of Action 113
R&D Progress 113
mRNA ACTR + rituximab - Drug Profile 115
Product Description 115
Mechanism Of Action 115
R&D Progress 115
MT-3724 - Drug Profile 117
Product Description 117
Mechanism Of Action 117
R&D Progress 117
olaptesed pegol - Drug Profile 119
Product Description 119
Mechanism Of Action 119
R&D Progress 119
ONO-4059 - Drug Profile 123
Product Description 123
Mechanism Of Action 123
R&D Progress 123
REGN-1979 - Drug Profile 125
Product Description 125
Mechanism Of Action 125
R&D Progress 125
SD-101 - Drug Profile 126
Product Description 126
Mechanism Of Action 126
R&D Progress 126
SNS-062 - Drug Profile 129
Product Description 129
Mechanism Of Action 129
R&D Progress 129
TAB-08 - Drug Profile 131
Product Description 131
Mechanism Of Action 131
R&D Progress 131
tocilizumab - Drug Profile 133
Product Description 133
Mechanism Of Action 133
R&D Progress 133
B-Cell Chronic Lymphocytic Leukemia - Dormant Projects 141
B-Cell Chronic Lymphocytic Leukemia - Discontinued Products 144
B-Cell Chronic Lymphocytic Leukemia - Product Development Milestones 145
Featured News & Press Releases 145
Apr 06, 2015: Juno Therapeutics Announces Patent Litigation Settlement 145
Nov 15, 2011: TheraMAB launches Phase I clinical trial of first-in-class agonistic monoclonal antibody TAB08 in Russia 145
Appendix 146
Methodology 146
Coverage 146
Secondary Research 146
Primary Research 146
Expert Panel Validation 146
Contact Us 146
Disclaimer 147

List of Tables

Number of Products under Development for B-Cell Chronic Lymphocytic Leukemia, H2 2016 11
Number of Products under Development for B-Cell Chronic Lymphocytic Leukemia - Comparative Analysis, H2 2016 12
Number of Products under Development by Companies, H2 2016 14
Number of Products under Investigation by Universities/Institutes, H2 2016 15
Comparative Analysis by Late Stage Development, H2 2016 16
Comparative Analysis by Clinical Stage Development, H2 2016 17
Comparative Analysis by Early Stage Development, H2 2016 18
Products under Development by Companies, H2 2016 19
Products under Development by Companies, H2 2016 (Contd..1) 20
Products under Investigation by Universities/Institutes, H2 2016 21
B-Cell Chronic Lymphocytic Leukemia - Pipeline by AB Science SA, H2 2016 22
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Aduro BioTech, Inc., H2 2016 23
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Amgen Inc., H2 2016 24
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Celgene Corporation, H2 2016 25
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Cell Source, Inc., H2 2016 26
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Dynavax Technologies Corporation, H2 2016 27
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Eisai Co., Ltd., H2 2016 28
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Elsalys Biotech SAS, H2 2016 29
B-Cell Chronic Lymphocytic Leukemia - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 30
B-Cell Chronic Lymphocytic Leukemia - Pipeline by iDD biotech SAS, H2 2016 31
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Immunomedics, Inc., H2 2016 32
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Johnson & Johnson, H2 2016 33
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Juno Therapeutics Inc., H2 2016 34
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Lymphocyte Activation Technologies, S.A., H2 2016 35
B-Cell Chronic Lymphocytic Leukemia - Pipeline by MedImmune, LLC, H2 2016 36
B-Cell Chronic Lymphocytic Leukemia - Pipeline by MEI Pharma, Inc., H2 2016 37
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Millennium Pharmaceuticals Inc, H2 2016 38
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Molecular Templates Inc., H2 2016 39
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Noxxon Pharma AG, H2 2016 40
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016 41
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Regeneron Pharmaceuticals Inc, H2 2016 42
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Sunesis Pharmaceuticals, Inc., H2 2016 43
B-Cell Chronic Lymphocytic Leukemia - Pipeline by TheraMAB LLC, H2 2016 44
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Unum Therapeutics, Inc., H2 2016 45
Assessment by Monotherapy Products, H2 2016 46
Assessment by Combination Products, H2 2016 47
Number of Products by Stage and Target, H2 2016 49
Number of Products by Stage and Mechanism of Action, H2 2016 51
Number of Products by Stage and Route of Administration, H2 2016 53
Number of Products by Stage and Molecule Type, H2 2016 55
B-Cell Chronic Lymphocytic Leukemia - Dormant Projects, H2 2016 141
B-Cell Chronic Lymphocytic Leukemia - Dormant Projects (Contd..1), H2 2016 142
B-Cell Chronic Lymphocytic Leukemia - Dormant Projects (Contd..2), H2 2016 143
B-Cell Chronic Lymphocytic Leukemia - Discontinued Products, H2 2016 144